（18）18F-FDG PET在肉瘤治疗反应成像中的应用
(18)F-FDG PET in sarcoma treatment response imaging.
作者信息
Eary Janet F, Hawkins Douglas S, Rodler Eve T, Conrad Ernest U
机构信息
University of Washington, Departments of Radiology, Orthopedics, and Pathology; Seattle Children's Hospital, Division of Oncology Seattle, WA, USA.
出版信息
Am J Nucl Med Mol Imaging. 2011;1(1):47-53. Epub 2011 Jun 23.
Abstract
Sarcomas are a biologically complex group of diseases that exhibit variable responses to single or combination therapy. (18)F-FDG PET imaging contributes to sarcoma treatment response assessment as an objective semiquantitative biomarker of response. In this review, background and experience in (18)F-FDG PET as a biomarker that successfully identifies tumor response is assessed.
摘要
肉瘤是一组生物学特性复杂的疾病，对单一疗法或联合疗法表现出不同的反应。（18）F-FDG PET成像作为一种客观的反应半定量生物标志物，有助于评估肉瘤的治疗反应。在本综述中，我们评估了（18）F-FDG PET作为一种成功识别肿瘤反应的生物标志物的背景和经验。
相似文献
1
(18)F-FDG PET in sarcoma treatment response imaging.
Am J Nucl Med Mol Imaging. 2011;1(1):47-53. Epub 2011 Jun 23.
2
The impact of F-FDG PET on initial staging and therapy planning of pediatric soft-tissue sarcoma patients.
Pediatr Radiol. 2020 Feb;50(2):252-260. doi: 10.1007/s00247-019-04530-1. Epub 2019 Oct 18.
3
18F-FES and 18F-FDG PET for differential diagnosis and quantitative evaluation of mesenchymal uterine tumors: correlation with immunohistochemical analysis.
J Nucl Med. 2013 Apr;54(4):499-506. doi: 10.2967/jnumed.112.113472. Epub 2013 Mar 7.
4
Combined 18F-NaF and 18F-FDG PET/CT in the Evaluation of Sarcoma Patients.
Clin Nucl Med. 2015 Sep;40(9):720-4. doi: 10.1097/RLU.0000000000000845.
5
18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.
Pediatr Hematol Oncol. 2011 Oct;28(7):579-87. doi: 10.3109/08880018.2011.602180.
6
Differentiation of soft tissue and bone sarcomas from benign lesions utilizing F-FDG PET/CT-derived parameters.
BMC Med Imaging. 2020 Jul 25;20(1):85. doi: 10.1186/s12880-020-00486-z.
7
Advantages of F FDG-PET/CT over Conventional Staging for Sarcoma Patients.
Pathol Oncol Res. 2019 Jan;25(1):131-136. doi: 10.1007/s12253-017-0325-0. Epub 2017 Oct 9.
8
The Role of F-FDG-PET/CT in Pediatric Sarcoma.
Semin Nucl Med. 2017 May;47(3):229-241. doi: 10.1053/j.semnuclmed.2016.12.004. Epub 2017 Jan 18.
9
Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
Ann Surg. 2000 Mar;231(3):380-6. doi: 10.1097/00000658-200003000-00011.
10
Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?
J Pediatr Hematol Oncol. 2012 Mar;34(2):131-6. doi: 10.1097/MPH.0b013e3182282825.
引用本文的文献
1
A novel silicone derivative of natural osalmid (DCZ0858) exerts anti-multiple myeloma activity by promoting cell apoptosis and inhibiting cell cycle and mTOR signaling.
Am J Transl Res. 2021 Oct 15;13(10):11439-11449. eCollection 2021.
2
Incremental Value of FDG-PET in the Evaluation of Cardiac Masses.
Curr Cardiol Rep. 2021 Jun 3;23(7):78. doi: 10.1007/s11886-021-01509-z.
3
Radionuclide generators: the prospect of availing PET radiotracers to meet current clinical needs and future research demands.
Am J Nucl Med Mol Imaging. 2019 Feb 15;9(1):30-66. eCollection 2019.
4
A Review on Green Synthesis, Biomedical Applications, and Toxicity Studies of ZnO NPs.
Bioinorg Chem Appl. 2018 Aug 1;2018:3569758. doi: 10.1155/2018/3569758. eCollection 2018.
5
Is PET-CT an accurate method for the differential diagnosis between chondroma and chondrosarcoma?
Springerplus. 2016 Feb 29;5:236. doi: 10.1186/s40064-016-1782-8. eCollection 2016.
6
Monitoring bone and soft-tissue tumors after carbon-ion radiotherapy using ¹⁸F-FDG positron emission tomography: a retrospective cohort study.
Radiat Oncol. 2015 Dec 21;10:259. doi: 10.1186/s13014-015-0571-9.
7
Evaluation of 68Ga-labeled MG7 antibody: a targeted probe for PET/CT imaging of gastric cancer.
Sci Rep. 2015 Mar 3;5:8626. doi: 10.1038/srep08626.
8
Prognostic relevance of ¹⁸F-FDG PET uptake in patients with locally advanced, extremity soft tissue sarcomas undergoing neoadjuvant isolated limb perfusion with TNF-α and melphalan.
Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1076-83. doi: 10.1007/s00259-013-2680-8. Epub 2014 Feb 12.
9
Intraoperative targeted optical imaging: a guide towards tumor-free margins in cancer surgery.
Curr Pharm Biotechnol. 2013;14(8):733-42. doi: 10.2174/1389201014666131226113300.
10
Positron emission tomography imaging of atherosclerosis.
Theranostics. 2013 Nov 2;3(11):894-902. doi: 10.7150/thno.5506.
本文引用的文献
1
A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.
Ann Surg Oncol. 2009 Apr;16(4):910-9. doi: 10.1245/s10434-008-0177-7. Epub 2008 Oct 25.
2
Combined assessment of metabolic and volumetric changes for assessment of tumor response in patients with soft-tissue sarcomas.
J Nucl Med. 2008 Oct;49(10):1579-84. doi: 10.2967/jnumed.108.053694. Epub 2008 Sep 15.
3
Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET.
Ann Nucl Med. 2008 Jul;22(6):475-80. doi: 10.1007/s12149-008-0147-y. Epub 2008 Aug 1.
4
Selection of response criteria for clinical trials of sarcoma treatment.
Oncologist. 2008;13 Suppl 2:32-40. doi: 10.1634/theoncologist.13-S2-32.
5
PET for sarcomas other than gastrointestinal stromal tumors.
Oncologist. 2008;13 Suppl 2:22-6. doi: 10.1634/theoncologist.13-S2-22.
6
Prognostic significance of 18F-FDG uptake in primary osteosarcoma after but not before chemotherapy: a possible association with autocrine motility factor/phosphoglucose isomerase expression.
Clin Exp Metastasis. 2008;25(4):427-35. doi: 10.1007/s10585-008-9147-5. Epub 2008 Feb 27.
7
Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas.
Clin Cancer Res. 2008 Feb 1;14(3):715-20. doi: 10.1158/1078-0432.CCR-07-1762.
8
The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas.
Expert Rev Mol Diagn. 2008 Jan;8(1):105-19. doi: 10.1586/14737159.8.1.105.
9
CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
AJR Am J Roentgenol. 2007 Dec;189(6):W324-30. doi: 10.2214/AJR.07.2496.
10
PET imaging: update on sarcomas.
Oncology (Williston Park). 2007 Feb;21(2):249-52.
Zotero 插件